Clinical Trial Update: Tislelizumab Consolidation Therapy After Radiotherapy or Sequential Chemoradiation in Locally Advanced NSCLC Patients [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating tislelizumab as consolidation immunotherapy after radiotherapy or sequential chemoradiation in patients with locally adva…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Tislelizumab (tislelizumab)

Snippet

Sponsor: Peking University Cancer Hospital & Institute | Conditions: Non-small Cell Lung Cancer, Consolidation Immunotherapy | Phase 2 | Status: RECRUITING